ArticleMolecular medicine reports2021

Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.

Yingjie Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.